Table 2. Relationship between genetic abnormalities and patient survival.
|
Myeloma IX
n=869 |
Myeloma XI
n=1036 |
Combined
n=1905 |
Heterogeneity | ||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | P-value | |
| (a) Progression-free survival | |||||||
| t(4;14) | 1.88 (1.52–2.23) | 5.31 × 10−9 | 1.51 (1.22–1.88) | 0.0001 | 1.69 (1.45–1.96) | 9.30 × 10−12 | 0.16 |
| t(14;16) | 1.50 (1.01–2.22) | 0.0425 | 1.51 (1.05–2.17) | 0.0256 | 1.50 (1.15–1.96) | 0.0026 | 0.98 |
| t(14;20) | 1.13 (0.64–1.99) | 0.6852 | 1.54 (0.80–2.97) | 0.1987 | 1.29 (0.84–1.98) | 0.2509 | 0.48 |
| Adverse translocations | 1.77 (1.47–2.13) | 1.88 × 10−9 | 1.58 (1.31–1.91) | 2.05 × 10−6 | 1.67 (1.46–1.91) | 2.69 × 10−14 | 0.41 |
| Del(17p) | 1.54 (1.21–1.95) | 0.0003 | 1.61 (1.26–2.06) | 0.0002 | 1.57 (1.33–1.87) | 2.07 × 10−7 | 0.79 |
| Gain(1q) | 1.53 (1.33–1.77) | 6.70 × 10−9 | 1.53 (1.31–1.80) | 1.34 × 10−7 | 1.53 (1.38–1.71) | 4.61 × 10−15 | 1.00 |
| Del(1p32) | 0.99 (0.78–1.25) | 0.9202 | 1.30 (1.02–1.66) | 0.0331 | 1.13 (0.95–1.34) | 0.1571 | 0.11 |
| ISS II | 1.40 (1.12–1.76) | 0.0036 | 1.54 (1.23–1.92) | 0.0002 | 1.47 (1.25–1.72) | 2.50 × 10−6 | 0.58 |
| ISS III | 1.64 (1.30–2.06) | 2.34 × 10−5 | 2.46 (1.96–3.09) | 6.88 × 10−16 | 2.02 (1.71–2.37) | 1.73 × 10−17 | 0.01 |
| 1 Adverse lesion | 1.41 (1.21–1.65) | 1.73 × 10−5 | 1.46 (1.23–1.74) | 1.44 × 10−5 | 1.44 (1.28–1.61) | 1.07 × 10−9 | 0.76 |
| ‘Double hit’ >1 adverse lesion | 2.24 (1.83–2.76) | 1.11 × 10−14 | 2.22 (1.78–2.77) | 1.05 × 10−12 | 2.23 (1.92–2.59) | 7.92 × 10−26 | 0.94 |
| Intermediate risk-ISS | 1.50 (1.25–1.79) | 1.48 × 10−5 | 1.95 (1.63–2.33) | 1.56 × 10−13 | 1.71 (1.51–1.95) | 9.48 × 10−17 | 0.04 |
| ‘Double hit’-ISS | 2.76 (2.13–3.57) | 1.54 × 10−14 | 2.93 (2.29–3.09) | 2 × 10−16 | 2.85 (2.38–3.40) | 8.32 × 10−31 | 0.74 |
|
Myeloma IX
n=869 |
Myeloma XI
n=1036 |
Combined
n=1905 |
Heterogeneity | ||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | P-value | |
| (b) OS | |||||||
| t(4;14) | 1.72 (1.36–2.17) | 5.12 × 10−6 | 1.42 (1.06–1.91) | 0.0188 | 1.60 (1.33–1.92) | 4.77 × 10−7 | 0.33 |
| t(14;16) | 1.52 (0.98–2.35) | 0.0607 | 2.00 (1.28–3.11) | 0.0021 | 1.74 (1.27–2.37) | 0.0005 | 0.39 |
| t(14;20) | 1.64 (0.88–3.07) | 0.1213 | 2.35 (1.11–4.97) | 0.0259 | 1.90 (1.17–3.07) | 0.0089 | 0.47 |
| Adverse translocations | 1.74 (1.42–2.14) | 1.15 × 10−7 | 1.71 (1.33–2.20) | 3.23 × 10−5 | 1.73 (1.47–2.03) | 1.63 × 10−11 | 0.90 |
| Del(17p) | 1.92 (1.49–2.48) | 6.07 × 10−7 | 2.40 (1.77–3.24) | 1.61 × 10−8 | 2.10 (1.73–2.56) | 8.86 × 10−14 | 0.27 |
| Gain(1q) | 1.61 (1.37–1.91) | 1.81 × 10−8 | 1.80 (1.44–2.24) | 1.76 × 10−7 | 1.68 (1.47–1.92) | 2.18 × 10−14 | 0.44 |
| Del(1p32) | 1.23 (0.94–1.61) | 0.1170 | 1.83 (1.35–2.48) | 0.0001 | 1.46 (1.20–1.78) | 0.0002 | 0.06 |
| ISS II | 1.98 (1.47–2.68) | 8.11 × 10−6 | 1.90 (1.30–2.77) | 0.0009 | 1.95 (1.54–2.47) | 2.76 × 10−8 | 0.86 |
| ISS III | 2.62 (1.94–3.53) | 2.69 × 10−10 | 3.85 (2.66–5.56) | 7.41 × 10−14 | 3.05 (2.42–3.85) | 4.38 × 10−21 | 0.11 |
| 1 Adverse lesion | 1.42 (1.18–1.71) | 0.0002 | 1.81 (1.41–2.32) | 3.57 × 10−6 | 1.55 (1.33–1.79) | 9.97 × 10−9 | 0.13 |
| ‘Double hit’ >1 Adverse lesion | 2.54 (2.02–3.18) | 7.77 × 10−16 | 2.91 (2.17–3.89) | 1.11 × 10−12 | 2.67 (2.23–3.19) | 8.13 × 10−27 | 0.47 |
| Intermediate risk-ISS | 1.96 (1.57–2.45) | 4.26 × 10−9 | 2.59 (1.96–3.41) | 1.62 × 10−11 | 2.19 (1.84–2.61) | 1.3 × 10−18 | 0.13 |
| ‘Double hit’-ISS | 3.93 (2.93–5.27) | 2 × 10−16 | 4.37 (3.13–6.12) | 2 × 10−16 | 4.12 (3.30–5.14) | 2.85 × 10−36 | 0.64 |
Abbreviations: CI, confidence interval; HR, hazard ratio; ISS, International Staging System; OS, overall survival.